Encephalomyeloneuropathy with CRMP-5 antibodies in a patient with a primary mediastinal serinoma
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received November 17, 2014
- Accepted in final form January 15, 2015
- First Published March 12, 2015.
Author Disclosures
- Cliff W. Hampton, MD,
- Dina Galperin, MD,
- Enrique Alvarez, MD and
- Matthew S. West, MD
- Cliff W. Hampton, MD,
NONE
NONE
NONE
1) Neurology, Resident & Fellow section. Editorial board member 2012-present.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Dina Galperin, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Enrique Alvarez, MD and
Teva neuroscience, Biogen IDEC, Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Matthew S. West, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Correspondence to Dr. West: matthew.west{at}ucdenver.edu
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritisSudarshini Ramanathan, Stephen W. Reddel, Andrew Henderson et al.Neurology - Neuroimmunology Neuroinflammation, October 29, 2014 -
Articles
Risk factors for developing multiple sclerosis after childhood optic neuritisC. F. Lucchinetti, L. Kiers, A. O'Duffy et al.Neurology, November 01, 1997 -
Articles
Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodiesClaudia F. Lucchinetti, David W. Kimmel, Vanda A. Lennon et al.Neurology, March 01, 1998 -
Articles
AQP4 antibody–positive Thai casesClinical features and diagnostic problemsS. Siritho, I. Nakashima, T. Takahashi et al.Neurology, August 03, 2011